This phase II trial studies how well fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography/computed tomography (PET/CT) imaging works in finding an area of abnormal tissue (lesion) both before and after the start of therapy in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Diagnostic procedures, such as 18F-FSPG PET/CT, may help find and diagnose lesions caused by cancer and monitor a patient's response to treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02599194.
PRIMARY OBJECTIVES:
I. Correlate the uptake of 18F-FSPG (fluorine F 18 L-glutamate derivative BAY94-9392), in patients with biopsy proven cancer, before and during therapy, to response to that therapy and patient outcomes.
SECONDARY OBJECTIVES:
I. Comparison of 18F-FSPG accumulation with other available imaging such as PET/CT (including but not limited to 18F-FDG [fludeoxyglucose F-18]), magnetic resonance imaging (MRI), and diagnostic computed tomography (CT).
II. Safety and tolerability of 18F-FSPG.
OUTLINE:
Patients receive fluorine F 18 L-glutamate derivative BAY94-9392 intravenously (IV) and 60 minutes after injection, undergo 18F-FSPG PET/CT before and after the start of therapy.
Lead OrganizationStanford Cancer Institute Palo Alto
Principal InvestigatorErik S. Mittra
